From lab to patient benefit: A panel discussion with Gunilla Osswald, Alumnus of the Year 2025
- Date
- 20 January 2026, 18:00–19:30
- Location
- Grand Auditorium
- Type
- Lecture
- Lecturer
- Gunilla Osswald
- Web page
- http://www.uu.se/20januari
- Organiser
- Development Office
- Contact person
- Jorja Zambars
How does a drug go from discovery to making a difference for patients? What happens along the way? Rector Anders Hagfeldt is pleased to welcome you to a panel discussion with Gunilla Osswald, Alumnus of the Year 2025.
%20Gunilla%20Osswald-0042.webp)
Please note – the panel discussion will be held in Swedish.
During her time as CEO of BioArctic, Gunilla Osswald has led the development of the first approved drug that slows down Alzheimer's disease.
During the evening, Gunilla Osswald will talk with researchers, business leaders and analysts about how science, innovation, ethics and economics interact in the complex world of drug development. What are the biggest challenges for future drug development? How can we ensure that new treatments reach the right patients in time, while addressing ethical and legal issues, and not least the regulatory requirements imposed on a new drug? And how can Sweden remain a leading nation in clinical development and innovation?
The discussion is open to everyone – whether you are a student, researcher or just curious. We are all dependent on effective and safe medicines, and this evening offers a unique insight into how the treatments of the future are being shaped.
A warm welcome to all!
Panel participants
- Gunilla Osswald, CEO, BioArctic
- Erik Hultgård, Analyst, DNB-Carnegie
- Sara Mangsbo, Professor, Department of Pharmacy, Uppsala University
- Karin Meyer, CEO, Center for Translational Research Sweden
- Anja Sandström, Professor, Department of Medicinal Chemistry at Uppsala University, Moderator
Registration
The event is free, but registration is required.
Read more and register at www.uu.se/20januari